Pegasus Asset Management’s Relmada Therapeutics RLMD Stock Holding History

Pegasus Asset Management’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-26,958	Closed	-$87.3K	–	68
2024 Q3	$87.3K	Hold	26,958	–	–	0.03%	70
2024 Q2	$80.9K	Hold	26,958	–	–	0.03%	71
2024 Q1	$125K	Hold	26,958	–	–	0.05%	69
2023 Q4	$112K	Hold	26,958	–	–	0.05%	69
2023 Q3	$80.9K	Hold	26,958	–	–	0.04%	70
2023 Q2	$66.3K	Hold	26,958	–	–	0.03%	71
2023 Q1	$60.9K	Hold	26,958	–	–	0.03%	69
2022 Q4	$94.1K	Hold	26,958	–	–	0.05%	71
2022 Q3	$998K	Hold	26,958	–	–	0.56%	46
2022 Q2	$512K	Hold	26,958	–	–	0.28%	59
2022 Q1	$728K	Hold	26,958	–	–	0.32%	61
2021 Q4	$607K	Hold	26,958	–	–	0.25%	64
2021 Q3	$707K	Hold	26,958	–	–	0.32%	61
2021 Q2	$863K	Hold	26,958	–	–	0.4%	58
2021 Q1	$949K	Hold	26,958	–	–	0.48%	55
2020 Q4	$865K	Hold	26,958	–	–	0.47%	53
2020 Q3	$1.01M	Hold	26,958	–	–	0.64%	49
2020 Q2	$1.21M	Buy	+26,958	New	+$1.14M	0.82%	43

Other funds holding RLMD

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Pegasus Asset Management's RLMD Position: Q4 2024 in Review

Pegasus Asset Management sold out of Relmada Therapeutics (RLMD) in Q4 2024, closing a stake of 26,958 shares — an estimated $87.3K sold.

Pegasus Asset Management first reported a position in RLMD in Q2 2020 and held it in 18 quarters. The position peaked at $1.21M in Q2 2020. 48 funds tracked by Wall St. Rank hold RLMD as of Q4 2024.

Pegasus Asset Management reported no remaining Relmada Therapeutics position as of Q4 2024 after selling out during the quarter.
Pegasus Asset Management sold 26,958 Relmada Therapeutics shares in Q4 2024, an estimated $87.3K.
Pegasus Asset Management first reported a position in Relmada Therapeutics in Q2 2020 and held it in 18 quarters.
Pegasus Asset Management's Relmada Therapeutics position peaked at $1.21M in Q2 2020.
48 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2024.

Based on Pegasus Asset Management's 13F filing for Q4 2024, filed 3 Feb 2025.